相关实验视频
Updated: Jul 9, 2025

08:49
Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
16.5K
生物使用与克罗恩氏病患者的术后并发症没有关联,这些患者经历了口腔回归
Zhenya Sun1, Tianrun Song2, Zhen Guo1
1Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
ANZ journal of surgery
|December 2, 2023
概括
在克罗恩病 (CD) 患者的口腔闭塞后,生物疗法没有增加并发症. 在手术前优化血红蛋白和白蛋白等因素是降低结节管逆转术后患病率的关键.
科学领域:
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
- 免疫学 免疫学 免疫学
背景情况:
- 胃口形成在克罗恩病 (CD) 中是常见的.
- 生物药物用于高风险的CD患者,但它们对口腔闭塞并发症的影响尚不清楚.
研究的目的:
- 评估生物暴露对CD患者静脉关闭后发病率的影响.
主要方法:
- 对347名经历了结节管切除术逆转的CD患者 (2013-2021) 的回顾性分析.
- 主要结局:90天的术后并发症.
- 生物和非生物组之间的比较.
主要成果:
- 两组之间感染并发症,整体并发症或住院时间没有显著差异.
- 患病率的预测因素包括低血红蛋白,高CRP,静脉部位问题,先前感染和低白蛋白.
结论:
- 生物使用与口腔闭塞后不良结果的增加无关.
- 优化手术前的因素,如血红蛋白,CRP,白蛋白,以及管理先前的感染,可以减少术后的发病率.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
148
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
148
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145

